Fine Industries has strengthened its board with the appointment of Dr. Christopher Richards as Non-Executive Director.
Dr Richards has held positions at Arysta LifeSciences Corporation as President and Chief Executive Officer and, prior to this, held various roles with leading crop protection specialist Sygenta. Under his leadership, Arysta LifeSciences was transformed into a major global agrochemical company, with one of the fastest growth rates in the industry. Since stepping down from the business, he has served on a variety of boards, both public and privately owned, predominantly involved in chemicals, pharmaceuticals and biotech.
In his role, Dr Richards will assist with the continued commercial and strategic development of Fine Industries. The Teesside-based manufacturer, which operates in key market segments including crop protection, pharmaceuticals and specialty chemicals, was backed by NorthEdge Capital with a £25m investment in 2013.
Under NorthEdge ownership the company has seen strong growth, with turnover increasing 25 per cent from £41m in 2013 to £51.4m in 2015 and employee numbers increasing from 241 to 305 today.
Dr. Christopher Richards said: “I am delighted to be joining Fine Industries, where we have a solid platform to build a world leading provider of fine chemicals. Despite operating in a tough marketplace, the business has been performing exceptionally well with the support of NorthEdge so it’s an exciting time to be getting on board.”
Ray Stenton, Partner and Head of New Business at NorthEdge, added: “This is a great move for Fine Industries. The board has gone from strength to strength and I am confident that Christopher’s industry knowledge and awareness of key customers will bring huge opportunities to the business.”
Chris Gowland, CEO of Fine Industries, commented “Christopher’s appointment will add further strength and depth to the board and I am delighted to be working with him to deliver a commercially focused growth strategy. Fine Industries continues to strengthen its offering in the market place and Christopher will play an important role in delivering a business strategy that is focused on exceptional people delivering exceptional performance for customers and stakeholders.”
Contact our press offices at MC2 for more information. firstname.lastname@example.org 0161 236 1352
Follow us on LinkedIn